MET three-lens brief
Evidence-based stock research on MET. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Analyst mean target $90.31 — 15% above current (16 analysts). · Negative free cash flow last quarterly (-$12.74B).
- Analyst mean target $90.31 — 15% above current (16 analysts).
- Negative free cash flow last quarterly (-$12.74B).
- Debt-to-equity of 226.0 — balance-sheet-heavy.
MET closed at $78.51 (-0.16%) as of 2026-05-13. Market cap: $50.52B. P/E (trailing) 15.2. Positives: analyst mean target $90.31 — 15% above current (16 analysts).. Concerns: negative free cash flow last quarterly (-$12.74B).; debt-to-equity of 226.0 — balance-sheet-heavy.. Last quarter: Revenue $24.19B, net income $778.00M, free cash flow -$12.74B.
Why three lenses on MET, not one.
A single reasoning model has blind spots it doesn’t know about. We examine METacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/MET" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath MET brief"></iframe>